Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 0.36 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.33 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28861085 | 0.87 | HRH3 (0.38) | HRH4HRH3HRH2TSHRHRH1 | |
| SCHEMBL3286058 | 0.86 | BACE1 (0.36) | HRH3BACE1NOS3NOS1NOS2 | |
| Bromide SCHEMBL28670044 | 0.86 | HRH3 (0.37) | HRH4HRH3HRH2TSHRHRH1 | |
| SCHEMBL4720914 | 0.85 | HRH4 (0.35) | HRH4HRH3HRH2APEX1SMN1; SMN2 | |
| Bromide SCHEMBL29291042 | 0.83 | HTR2A (0.43) | HTR1A | |
| SCHEMBL28227334 | 0.82 | HRH3 (0.34) | HRH3HTR1ANOS2 | |
| SCHEMBL3841860 | 0.81 | HRH3 (0.41) | HRH3NOS2 | |
| SCHEMBL2849132 | 0.81 | HTR2A (0.44) | TDP1HTR1ACYP2C9CYP2C19 | |
| SCHEMBL28228111 | 0.80 | HTR1A (0.33) | HRH4HRH3TSHRHTR1ACYP2C9 | |
| SCHEMBL3697323 | 0.80 | GLA (0.33) | HRH3BACE1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1039323-C | Imidazopyriding derivatives and process for preparation thereof | TANABE SEIYAKU CO (JP) | 1998-07-29 | — | — | CN | disclosed |
| EP-0531876-B1 | Imidazoindolizine derivatives and process for preparation thereof | TANABE SEIYAKU CO (JP) | 1996-12-18 | — | — | EP | disclosed |
| US-5510354-A | HYPOTENSIVE AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1996-04-23 | — | — | US | disclosed |
| US-5424316-A | Imidazopyridine derivatives for the treatment of hypertension | TANABE SEIYAKU CO., LTD. (JP) | 1995-06-13 | — | — | US | disclosed |
| US-5409936-A | Useful in prophylaxix; exhibits potent angiotensin ii inhibitory acivities | TANABE SEIYAKU CO., LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
| US-5268377-A | Imidazoindolizine derivatives process for preparation thereof and use thereof to treat hypertension | TANABE SEIYAKU CO., LTD. (JP) | 1993-12-07 | — | — | US | disclosed |
| CN-1070912-A | Imidazopyridine derivatives and preparation method thereof | TANABE SEIYAKU CO (JP) | 1993-04-14 | — | — | CN | disclosed |
| EP-0531876-A2 | Imidazoindolizine derivatives and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| EP-0531874-A1 | Imidazopyridine derivatives and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |